Impact of meropenem on Klebsiella pneumoniae metabolism
- PMID: 30440048
- PMCID: PMC6237392
- DOI: 10.1371/journal.pone.0207478
Impact of meropenem on Klebsiella pneumoniae metabolism
Abstract
The aim of this study was to analyze the metabolome of several Klebsiella pneumoniae strains characterized by different resistance patterns. A total of 59 bacterial strains (27 carbapenemase-negative and 32 carbapenemase-positive) were included and their metabolic features were assessed in basal conditions. Moreover, 8 isolates (4 wild-type and 4 KPC-producers) were randomly selected to evaluate the impact of sub-lethal concentrations of meropenem on bacterial metabolism. The metabolomic analysis was performed by 1H-NMR spectroscopy both on filtered supernatants and cell lysates. A total of 40 and 20 molecules were quantified in the intracellular and the extracellular metabolome, respectively. While in basal conditions only five metabolites showed significant differences between carbapenemase-positive and negative strains, the use of meropenem had a profound impact on the whole bacterial metabolism. In the intracellular compartment, a reduction of different overflow metabolites and organic acids (e.g. formate, acetate, isobutyrate) was noticed, whereas, in the extracellular metabolome, the levels of several organic acids (e.g. succinate, acetate, formate, lactate) and amino acids (aspartate, threonine, lysine, alanine) were modified by meropenem stimulation. Interestingly, carbapenemase-positive and negative strains reacted differently to meropenem in terms of number and type of perturbed metabolites. In wild-type strains, meropenem had great impact on the metabolic pathways related to methane metabolism and alanine, aspartate and glutamate metabolism, whereas in KPC-producers the effect was predominant on pyruvate metabolism. The knowledge about the bacterial metabolic profiles could help to set up innovative diagnostic methods and new antimicrobial strategies to fight the global crisis against carbapenemase-positive K. pneumoniae.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures



Similar articles
-
Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00794-17. doi: 10.1128/AAC.00794-17. Print 2017 Oct. Antimicrob Agents Chemother. 2017. PMID: 28760900 Free PMC article.
-
Effect of the meropenem MIC on the killing activity of meropenem and polymyxin B in combination against KPC-producing Klebsiella pneumoniae.J Antibiot (Tokyo). 2017 Aug;70(9):974-978. doi: 10.1038/ja.2017.73. Epub 2017 Jul 5. J Antibiot (Tokyo). 2017. PMID: 28676713 No abstract available.
-
Repurposing the anti-viral drug zidovudine (AZT) in combination with meropenem as an effective treatment for infections with multi-drug resistant, carbapenemase-producing strains of Klebsiella pneumoniae.Pathog Dis. 2020 Dec 9;78(9):ftaa063. doi: 10.1093/femspd/ftaa063. Pathog Dis. 2020. PMID: 33053176
-
Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae: a review of epidemiological and clinical aspects.Expert Opin Biol Ther. 2012 Jun;12(6):663-71. doi: 10.1517/14712598.2012.681369. Epub 2012 Apr 16. Expert Opin Biol Ther. 2012. PMID: 22506862 Review.
-
Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.Pharmacotherapy. 2018 Apr;38(4):444-461. doi: 10.1002/phar.2092. Epub 2018 Mar 28. Pharmacotherapy. 2018. PMID: 29427523 Review.
Cited by
-
The detection and utilization of volatile metabolomics in Klebsiella pneumoniae by gas chromatography-ion mobility spectrometry.Sci Rep. 2024 Oct 30;14(1):26122. doi: 10.1038/s41598-024-77746-3. Sci Rep. 2024. PMID: 39478041 Free PMC article.
-
Comparison of bacteria disintegration methods and their influence on data analysis in metabolomics.Sci Rep. 2021 Oct 21;11(1):20859. doi: 10.1038/s41598-021-99873-x. Sci Rep. 2021. PMID: 34675363 Free PMC article.
-
Sample Preparation in Microbial Metabolomics: Advances and Challenges.Adv Exp Med Biol. 2023;1439:149-183. doi: 10.1007/978-3-031-41741-2_7. Adv Exp Med Biol. 2023. PMID: 37843809
-
Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial.Metabolites. 2020 Jul 3;10(7):274. doi: 10.3390/metabo10070274. Metabolites. 2020. PMID: 32635406 Free PMC article.
-
Metabolic response of Klebsiella oxytoca to ciprofloxacin exposure: a metabolomics approach.Metabolomics. 2024 Dec 15;21(1):8. doi: 10.1007/s11306-024-02206-y. Metabolomics. 2024. PMID: 39676074 Free PMC article.
References
-
- Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25: 682–707. 10.1128/CMR.05035-11 - DOI - PMC - PubMed
-
- European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2015.
-
- Giani T, Pini B, Arena F, Conte V, Bracco S, Migliavacca R, et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill. 2013; 18: pii = 20489. - PubMed
-
- Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill. 2010;15: pii = 19711. - PubMed
-
- Diene SM, Rolain JM. Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species. Clin Microbiol Infect. 2014;20: 831–838. 10.1111/1469-0691.12655 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical